Our news

Crossject will be attending J.P. Morgan Healthcare conference

 January 13-16 2020, Crossject will be in San Francisco around the J.P. Morgan Healthcare Conference, to meet with American pharmaceutical companies.

Read more

Cooperative agreement signed between Crossject and the US Department of Defense

Crossject and the US Department of Defense have signed a cooperative research and development agreement for Zeneo® Midazolam

ZENEO® Midazolam earns the orphan drug designation

The FDA has granted Orphan Drug designation to ZENEO® Midazolam for the treatment of status epileptics.

ZENEO® receives the JANUS

Crossject is proud to announce that ZENEO® received the 2017 JANUS Prospective award from the French Institute of Design.